Jaguar Health, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Although the request refers to 2021 Q4, this filing reports full-year results; it does not provide a clear standalone fourth-quarter income statement or cash-flow figure.
Business context
Jaguar is a commercial-stage pharmaceutical company developing plant-based gastrointestinal medicines for people and animals. Its principal marketed human product is Mytesi (crofelemer), approved for noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy. Canalevia-CA1 received conditional FDA approval in December 2021 for chemotherapy-induced diarrhea in dogs; the company expected U.S. distributor availability in Q2 2022 following a manufacturing-controls update. The company is also developing crofelemer for cancer-therapy-related diarrhea and rare gastrointestinal diseases, and lechlemer for infectious diarrhea including cholera.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $4.335 million | $9.385 million |
| Cost of product revenue | $2.333 million | $3.280 million |
| Gross profit / gross margin, calculated from reported revenue and cost | $2.002 million / approximately 46% | $6.105 million / approximately 65% |
| Research and development expense | $15.079 million | $6.413 million |
| Sales and marketing expense | $8.894 million | $6.609 million |
| General and administrative expense | $17.103 million | $14.387 million |
| Operating loss | $40.708 million | $26.647 million |
| Interest expense | $8.421 million | $2.792 million |
| Net loss | $52.600 million | $33.809 million |
| Net loss per share, basic and diluted | $1.18 | $3.00 |
| Cash from operating activities | $(34.970) million | $(15.278) million |
| Cash from financing activities | $43.937 million | $19.492 million |
| Cash at year-end | $17.051 million | $8.090 million |
At December 31, 2021, total assets were $53.265 million, total liabilities $41.412 million, and stockholders’ equity $11.853 million. Current assets were $28.434 million and current liabilities $15.471 million. Notes payable were reported at $28.206 million net of discounts and issuance costs; the associated gross balance was $45.503 million. The company had an accumulated deficit of $219.494 million. No dividend is planned.
Material changes versus FY2020
- Revenue fell 53.8%. The company attributed much of the decline in Mytesi gross revenue to the transition from wholesaler distribution to a closed specialty-pharmacy network, including a one-time inventory drawdown of about 1,300 bottles. Net Mytesi revenue was $3.3 million versus $9.3 million.
- Medicaid rebates rose to $3.484 million from $1.738 million, primarily following the April 2020 wholesale acquisition cost increase; sales discounts declined to $6.268 million from $7.046 million.
- R&D expense rose 135.1%, driven by clinical-trial startup and activity, manufacturing/CMC work, and lechlemer research. Sales and marketing expense rose 34.6%, while G&A rose 18.9%.
- Operating cash use more than doubled. Financing proceeds increased, but included substantial equity and debt financing. Interest expense more than tripled, largely due to royalty-interest agreements.
- Net loss widened by $18.791 million. The reported per-share loss narrowed, while weighted-average shares increased substantially; the share count and reverse-split-adjusted figures should be considered when comparing periods.
Outlook, risks, contingencies, and unusual items
- Going concern and liquidity: Management and the auditor disclosed substantial doubt about the company’s ability to continue as a going concern. Management said year-end cash was insufficient to fund operations through one year from the March 11, 2022 filing date and that it had an immediate need to raise cash. Future operations depend on financing, commercialization, and development outcomes; no assurance was given that funding would be available on acceptable terms.
- Funding and potential dilution: In January–March 2022, the company sold 20.0 million shares under its ATM program for net proceeds of $9.2 million and increased the ATM authorization to $75 million. It also issued shares to reduce royalty balances. These actions provide cash or reduce obligations but dilute existing holders.
- Debt and royalty commitments: Disclosed minimum royalty payments were $6.0 million in 2022, $18.0 million in 2023, $13.9 million in 2024, $7.1 million in 2025, and $3.9 million in 2026. Contractual timing may vary with revenue. The Streeterville note is secured by lechlemer-related assets and includes trial-failure and default provisions; no trial failure or default was reported at year-end.
- Pipeline milestones are uncertain and funding-dependent: Enrollment was ongoing in the Phase 3 OnTarget cancer-therapy-related diarrhea trial. The company anticipated a Phase 2 proof-of-concept study for SBS and/or CDD in 2022, top-line results from a chronic idiopathic diarrhea study in 2022, and a lechlemer Phase 1 trial in the second half of 2022. These are expectations, not assurances.
- Canalevia-CA1: Conditional approval permits marketing while effectiveness evidence is completed, but requires annual renewals and eventual full approval. The company also expected conditional approval for Canalevia-CA2 for exercise-induced diarrhea in dogs in Q4 2022.
- Concentration and supply risks: Three customers accounted for 73%, 11%, and 12% of FY2021 revenue, respectively. The company relies on two raw-material suppliers and single third-party manufacturers for crofelemer API and finished product, and has a minimum annual crofelemer purchase commitment.
- Listing and controls: Nasdaq notified the company in February 2022 that its bid price had been below $1 for 30 consecutive business days, giving it until August 16, 2022 to regain compliance. Management reported disclosure controls and internal control over financial reporting effective at year-end and said prior material weaknesses had been remediated; the auditor did not attest to internal-control effectiveness.
- Other items: The auditor issued an unmodified opinion on the 2021 financial statements while highlighting the going-concern uncertainty. A 2017 merger-related class-action settlement received final court approval in 2021; the D&O insurer funded the $2.6 million settlement. The company reported no material active legal accrual at year-end. The FDA denied the company’s earlier EUA request for crofelemer for COVID-related symptoms.
Important facts for investors to verify
- Current cash, cash burn, financing availability, and the effect of post-year-end ATM share sales and other equity issuances on dilution.
- Actual Mytesi demand and net revenue after the specialty-pharmacy transition, including the effect of rebates, discounts, and customer concentration.
- Royalty and debt repayment schedules, covenants, security interests, and the company’s ability to meet minimum payments.
- Canalevia-CA1 distribution timing, CMC update status, annual conditional-approval renewal progress, and path to full approval.
- Clinical-trial enrollment, funding, data timing, and regulatory milestones for OnTarget, SBS/CDD, and lechlemer.
- Whether the company regained Nasdaq bid-price compliance by the stated deadline and the resulting impact on access to capital and trading liquidity.